Barclays lowered the firm’s price target on Bruker (BRKR) to $40 from $43 and keeps an Overweight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker Positioned for Recovery and Growth Amid Financial Maneuvering and Strategic Initiatives
- Bruker Raises $669.5 Million Through Underwriting Agreement
- Bruker Positioned for Growth with Strategic Financial Moves and Cost Savings Initiatives
- Alphabet jumps after avoiding worst case in antitrust ruling: Morning Buzz
- Bruker falls -11.3%